Across TCGA pan-cancer cohorts, TAF9B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TAF9B data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher TAF9B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAF9B expression acts as an unfavorable survival marker.

KICH, UCEC, and SKCM are the cancer types where TAF9B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	OS	Median	All	0.161	0.881	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.233	0.787	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TAF9B tumor-vs-normal RNA expression · all TAF9B data types